Endometrial Cancer Clinical Trials in Houston, Texas

41 studies are recruiting for endometrial cancer in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

  1. A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

    The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    28 in total
    Run by
    Jazz Pharmaceuticals

    See if you can join NCT06695845 on ClinicalTrials.gov

  2. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    A Study of Emi-Le in Participants with Solid Tumors

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson, Houston, Texas
    Locations
    26 in total
    Run by
    Day One Biopharmaceuticals, Inc.

    See if you can join NCT05377996 on ClinicalTrials.gov

  3. Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

    To learn if chemotherapy given in combination with radiation therapy, followed by maintenance therapy, can help to control endometrial cancer. The safety and effects of this study treatment will also be studied

    Stage
    Phase 1
    Ages
    18 and older
    Site
    M D Anderson Cancer Center, Houston, Texas
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT05819892 on ClinicalTrials.gov

  4. A Study of Lorigerlimab in Participants With Advanced Solid Tumors

    Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    The University of Texas MD Anderson Cancer Center, Gynecologic Oncology Center, Houston, Texas
    Locations
    16 in total
    Run by
    MacroGenics

    See if you can join NCT06730347 on ClinicalTrials.gov

  5. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    6 in total
    Run by
    ModeX Therapeutics, An OPKO Health Company

    See if you can join NCT06239194 on ClinicalTrials.gov

  6. Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

    The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This prop…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Total Women's Care of the Heights, Houston, Texas
    Locations
    24 in total
    Run by
    Mayo Clinic

    See if you can join NCT05051722 on ClinicalTrials.gov

  7. EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

    The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    10 in total
    Run by
    Eikon Therapeutics

    See if you can join NCT07262619 on ClinicalTrials.gov

  8. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    14 in total
    Run by
    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

  9. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Oncology Consultants, P.A., Houston, Texas
    Locations
    39 in total
    Run by
    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

  10. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

    This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    6 in total
    Run by
    Tanabe Pharma America, Inc.

    See if you can join NCT06943521 on ClinicalTrials.gov

  11. A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

    The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.

    Stage
    Phase 2
    Ages
    18 to 70
    Site
    MD Anderson Cancer Center - U of Texas, Houston, Texas
    Locations
    12 in total
    Run by
    Iovance Biotherapeutics, Inc.

    See if you can join NCT06481592 on ClinicalTrials.gov

  12. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Houston, Texas
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  13. Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer

    This is a prospective, multi-center, randomized non-inferiority phase III study to evaluate if patients undergoing a minimally invasive surgery for early stage uterine cancer have cancer cells in the fluid that is obtained at the time of their surgery when a uterine manipulator is placed versus pat…

    Stage
    Not phased
    Ages
    18 to 90
    Site
    Baylor College of Medicine- McNair Campus, Houston, Texas
    Locations
    5 in total
    Run by
    Anthony Costales, MD

    See if you can join NCT04586959 on ClinicalTrials.gov

  14. A Beta-only IL-2 ImmunoTherapY Study

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    27 in total
    Run by
    Medicenna Therapeutics, Inc.

    See if you can join NCT05086692 on ClinicalTrials.gov

  15. BP1001-A in Patients With Advanced or Recurrent Solid Tumors

    This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is es…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Texas M.D. Anderson Cancer Center, Houston, Texas
    Locations
    4 in total
    Run by
    Bio-Path Holdings, Inc.

    See if you can join NCT04196257 on ClinicalTrials.gov

  16. Comprehensive Outcomes for After Cancer Health

    This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to pa…

    Stage
    Not phased
    Ages
    18 and older
    Site
    UT Health Houston, Houston, Texas
    Locations
    7 in total
    Run by
    Pack Health

    See if you can join NCT05349227 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.